Related Experiment Video
Updated: Jan 15, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
Published on: November 8, 2024
Trends in Opioid Prescribing and Co-Prescription of Opioid Antagonists: A Retrospective Analysis over a 12-Month
Jamal Hasoon1, Ahmed Abdalla2, Giuliano Lo Bianco3
1Hasoon, Department of Anesthesiology, Critical Care, and Pain Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Background:
Opioid prescribing practices have come under increased scrutiny due to the ongoing opioid crisis, with efforts focusing on harm reduction strategies such as co-prescription of opioid antagonists. This study analyzes opioid prescribing trends and the frequency of opioid-antagonist co-prescription over the course of 2024.
Methods:
A retrospective analysis was performed using electronic medical record data to identify all opioid prescriptions issued between January 1, 2024, and December 31, 2024. Each opioid prescription was cross-referenced with any concurrent prescription for an opioid antagonist. The analysis did not differentiate opioid type, duration of therapy, or prescribing indication.
Results:
A total of 68,212 opioid prescriptions were issued in 2024. Quarterly totals were: Q1: 16,574; Q2: 16,882; Q3: 16,922; and Q4: 17,834. Among these, 7,586 (11.1%) were co-prescribed with an opioid antagonist, while 60,626 (88.9%) were not. The distribution across quarters was:Q1: 16,574 prescriptionsQ2: 16,882 prescriptionsQ3: 16,922 prescriptionsQ4: 17,834 prescriptionsOf these, 7,586 (11.1%) were co-prescribed with an opioid antagonist, while 60,626 (88.9%) were prescribed without one. The quarterly breakdown of opioid-antagonist co-prescription was:Q1: 1,874 prescriptions with an antagonist, 14,700 withoutQ2: 1,867 prescriptions with an antagonist, 15,015 withoutQ3: 1,945 prescriptions with an antagonist, 14,977 withoutQ4: 1,900 prescriptions with an antagonist, 15,934 without.
Conclusion:
Despite ongoing recommendations to increase opioid-antagonist co-prescription, a large majority (88.9%) of opioid prescriptions in 2024 were issued without an antagonist. While there was a modest increase in overall opioid prescriptions over the year, opioid-antagonist co-prescription rates remained relatively stable. These findings highlight the need for further investigation into barriers preventing wider adoption of opioid-antagonist co-prescription and the potential impact on patient safety.
More Related Videos
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Opioid Receptors: Overview

